PMID- 38385495
OWN - NLM
STAT- Publisher
LR  - 20240222
IS  - 1873-5576 (Electronic)
IS  - 1568-0096 (Linking)
DP  - 2024 Feb 21
TI  - Insights into the Emerging Therapeutic Targets of Triple-negative Breast Cancer.
LID - 10.2174/0115680096280750240123054936 [doi]
AB  - Triple-negative Breast Cancer (TNBC), the most aggressive breast cancer subtype, 
      is characterized by the non-appearance of estrogen receptor (ER), progesterone 
      receptor (PR), and human epidermal growth factor receptor 2 (HER2). Clinically, 
      TNBC is marked by its low survival rate, poor therapeutic outcomes, high 
      aggressiveness, and lack of targeted therapies. Over the past few decades, many 
      clinical trials have been ongoing for targeted therapies in TNBC. Although some 
      classes, such as Poly (ADP Ribose) Polymerase (PARP) inhibitors and 
      immunotherapies, have shown positive therapeutic outcomes, however, clinical 
      effects are not much satisfiable. Moreover, the development of drug resistance is 
      the major pattern observed in many targeted monotherapies. The heterogeneity of 
      TNBC might be the cause for limited clinical benefits. Hence,, there is a need 
      for the potential identification of new therapeutic targets to address the above 
      limitations. In this context, some novel targets that can address the 
      above-mentioned concerns are emerging in the era of TNBC therapy, which include 
      Hypoxia Inducible Factor (HIF-1alpha), Matrix Metalloproteinase 9 (MMP-9), Tumour 
      Necrosis Factor-alpha (TNF-alpha), beta-Adrenergic Receptor (beta-AR), Voltage Gated Sodium 
      Channels (VGSCs), and Cell Cycle Regulators. Currently, we summarize the ongoing 
      clinical trials and discuss the novel therapeutic targets in the management of 
      TNBC.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Varshini, Magham Sai
AU  - Varshini MS
AD  - Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher 
      Education and Research, Ooty- 643001, TN, India.
FAU - Krishnamurthy, Praveen Thaggikuppe
AU  - Krishnamurthy PT
AD  - Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher 
      Education and Research, Ooty- 643001, TN, India.
FAU - Reddy, Ramakamma Aishwarya
AU  - Reddy RA
AD  - Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher 
      Education and Research, Ooty- 643001, TN, India.
FAU - Wadhwani, Ashish
AU  - Wadhwani A
AD  - Department of Pharmaceutical Biotechnology, JSS College of Pharmacy, JSS Academy 
      of Higher Education and Research, Ooty- 643001, TN, India.
AD  - Faculty of Health Sciences, School of Pharmacy, JSS Academy of Higher Education 
      and Research, Mauritius, Vacoas - 73304, Mauritius.
FAU - Chandrashekar, V M
AU  - Chandrashekar VM
AD  - Department of Pharmacology, HSK College of Pharmacy, Bagalkot- 587101, Karnataka, 
      India.
LA  - eng
PT  - Journal Article
DEP - 20240221
PL  - Netherlands
TA  - Curr Cancer Drug Targets
JT  - Current cancer drug targets
JID - 101094211
SB  - IM
OTO - NOTNLM
OT  - Triple negative breast cancer
OT  - hypoxia inducible factor-1alpha
OT  - matrix metalloproteinase-9
OT  - tumour necrosis factor-alpha
OT  - voltage gated sodium channels.
OT  - beta-adrenergic receptor
EDAT- 2024/02/22 12:43
MHDA- 2024/02/22 12:43
CRDT- 2024/02/22 07:54
PHST- 2023/09/23 00:00 [received]
PHST- 2023/12/24 00:00 [revised]
PHST- 2024/01/09 00:00 [accepted]
PHST- 2024/02/22 12:43 [medline]
PHST- 2024/02/22 12:43 [pubmed]
PHST- 2024/02/22 07:54 [entrez]
AID - CCDT-EPUB-138654 [pii]
AID - 10.2174/0115680096280750240123054936 [doi]
PST - aheadofprint
SO  - Curr Cancer Drug Targets. 2024 Feb 21. doi: 10.2174/0115680096280750240123054936.